Matches in SemOpenAlex for { <https://semopenalex.org/work/W4303457093> ?p ?o ?g. }
- W4303457093 endingPage "516" @default.
- W4303457093 startingPage "508" @default.
- W4303457093 abstract "Although chemoimmunotherapy is widely used for treatment of children with relapsed high-risk neuroblastoma (HRNB), little is known about timing, duration, and evolution of response after irinotecan/temozolomide/dinutuximab/granulocyte-macrophage colony-stimulating factor (I/T/DIN/GM-CSF) therapy.Patients eligible for this retrospective study were age < 30 years at diagnosis of HRNB and received ≥ 1 cycle of I/T/DIN/GM-CSF for relapsed or progressive disease. Patients with primary refractory disease who progressed through induction were excluded. Responses were evaluated using the International Neuroblastoma Response Criteria.One hundred forty-six patients were included. Tumors were MYCN-amplified in 50 of 134 (37%). Seventy-one patients (49%) had an objective response to I/T/DIN/GM-CSF (objective response; 29% complete response, 14% partial response [PR], 5% minor response [MR], 21% stable disease [SD], and 30% progressive disease). Of patients with SD or better at first post-I/T/DIN/GM-CSF disease evaluation, 22% had an improved response per International Neuroblastoma Response Criteria on subsequent evaluation (13% of patients with initial SD, 33% with MR, and 41% with PR). Patients received a median of 4.5 (range, 1-31) cycles. The median progression-free survival (PFS) was 13.1 months, and the 1-year PFS and 2-year PFS were 50% and 28%, respectively. The median duration of response was 15.9 months; the median PFS off all anticancer therapy was 10.4 months after discontinuation of I/T/DIN/GM-CSF.Approximately half of patients receiving I/T/DIN/GM-CSF for relapsed HRNB had objective responses. Patients with initial SD were unlikely to have an objective response, but > 1 of 3 patients with MR/PR on first evaluation ultimately had complete response. I/T/DIN/GM-CSF was associated with extended PFS in responders both during and after discontinuation of treatment. This study establishes a new comparator for response and survival in patients with relapsed HRNB." @default.
- W4303457093 created "2022-10-07" @default.
- W4303457093 creator A5000453742 @default.
- W4303457093 creator A5001272024 @default.
- W4303457093 creator A5014330639 @default.
- W4303457093 creator A5017202683 @default.
- W4303457093 creator A5019748093 @default.
- W4303457093 creator A5023262828 @default.
- W4303457093 creator A5024115933 @default.
- W4303457093 creator A5028980058 @default.
- W4303457093 creator A5032694320 @default.
- W4303457093 creator A5035557509 @default.
- W4303457093 creator A5036062620 @default.
- W4303457093 creator A5036077095 @default.
- W4303457093 creator A5040815350 @default.
- W4303457093 creator A5046612625 @default.
- W4303457093 creator A5048601340 @default.
- W4303457093 creator A5051711134 @default.
- W4303457093 creator A5061278042 @default.
- W4303457093 creator A5064788392 @default.
- W4303457093 creator A5064799427 @default.
- W4303457093 creator A5068808085 @default.
- W4303457093 creator A5073092034 @default.
- W4303457093 creator A5077754316 @default.
- W4303457093 creator A5084270347 @default.
- W4303457093 date "2023-01-20" @default.
- W4303457093 modified "2023-10-06" @default.
- W4303457093 title "Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor" @default.
- W4303457093 cites W1986399662 @default.
- W4303457093 cites W2018717541 @default.
- W4303457093 cites W2063960043 @default.
- W4303457093 cites W2114441352 @default.
- W4303457093 cites W2127478952 @default.
- W4303457093 cites W2147800896 @default.
- W4303457093 cites W2152420890 @default.
- W4303457093 cites W2153188415 @default.
- W4303457093 cites W2158683596 @default.
- W4303457093 cites W2341800449 @default.
- W4303457093 cites W2611071372 @default.
- W4303457093 cites W2618869560 @default.
- W4303457093 cites W2735902464 @default.
- W4303457093 cites W2899367264 @default.
- W4303457093 cites W2980942118 @default.
- W4303457093 cites W3018670999 @default.
- W4303457093 cites W3031848108 @default.
- W4303457093 cites W3042066551 @default.
- W4303457093 cites W3123833440 @default.
- W4303457093 cites W3164659665 @default.
- W4303457093 cites W3184057816 @default.
- W4303457093 doi "https://doi.org/10.1200/jco.22.01273" @default.
- W4303457093 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36206505" @default.
- W4303457093 hasPublicationYear "2023" @default.
- W4303457093 type Work @default.
- W4303457093 citedByCount "5" @default.
- W4303457093 countsByYear W43034570932023 @default.
- W4303457093 crossrefType "journal-article" @default.
- W4303457093 hasAuthorship W4303457093A5000453742 @default.
- W4303457093 hasAuthorship W4303457093A5001272024 @default.
- W4303457093 hasAuthorship W4303457093A5014330639 @default.
- W4303457093 hasAuthorship W4303457093A5017202683 @default.
- W4303457093 hasAuthorship W4303457093A5019748093 @default.
- W4303457093 hasAuthorship W4303457093A5023262828 @default.
- W4303457093 hasAuthorship W4303457093A5024115933 @default.
- W4303457093 hasAuthorship W4303457093A5028980058 @default.
- W4303457093 hasAuthorship W4303457093A5032694320 @default.
- W4303457093 hasAuthorship W4303457093A5035557509 @default.
- W4303457093 hasAuthorship W4303457093A5036062620 @default.
- W4303457093 hasAuthorship W4303457093A5036077095 @default.
- W4303457093 hasAuthorship W4303457093A5040815350 @default.
- W4303457093 hasAuthorship W4303457093A5046612625 @default.
- W4303457093 hasAuthorship W4303457093A5048601340 @default.
- W4303457093 hasAuthorship W4303457093A5051711134 @default.
- W4303457093 hasAuthorship W4303457093A5061278042 @default.
- W4303457093 hasAuthorship W4303457093A5064788392 @default.
- W4303457093 hasAuthorship W4303457093A5064799427 @default.
- W4303457093 hasAuthorship W4303457093A5068808085 @default.
- W4303457093 hasAuthorship W4303457093A5073092034 @default.
- W4303457093 hasAuthorship W4303457093A5077754316 @default.
- W4303457093 hasAuthorship W4303457093A5084270347 @default.
- W4303457093 hasConcept C121608353 @default.
- W4303457093 hasConcept C126322002 @default.
- W4303457093 hasConcept C141071460 @default.
- W4303457093 hasConcept C143998085 @default.
- W4303457093 hasConcept C2776694085 @default.
- W4303457093 hasConcept C2776715637 @default.
- W4303457093 hasConcept C2776755627 @default.
- W4303457093 hasConcept C2777389519 @default.
- W4303457093 hasConcept C2777767877 @default.
- W4303457093 hasConcept C2778822529 @default.
- W4303457093 hasConcept C2780259306 @default.
- W4303457093 hasConcept C2780739268 @default.
- W4303457093 hasConcept C2780790343 @default.
- W4303457093 hasConcept C526805850 @default.
- W4303457093 hasConcept C54355233 @default.
- W4303457093 hasConcept C71924100 @default.
- W4303457093 hasConcept C81885089 @default.
- W4303457093 hasConcept C86803240 @default.
- W4303457093 hasConcept C90924648 @default.